Drug Profile
Formoterol/glycopyrrolate inhalation - Glenmark Pharmaceuticals
Alternative Names: Glycopyrronium/formoterol fumarateLatest Information Update: 01 Dec 2020
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Antiasthmatics; Antispasmodics; Antiulcers; Bronchodilators; Ethanolamines; Pyrrolidines; Quaternary ammonium compounds; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
Most Recent Events
- 01 Dec 2020 Launched for Chronic obstructive pulmonary disease in India (Inhalation) before December 2020
- 28 Jan 2019 Chemical structure information added
- 13 Nov 2018 Jawahar Lal Nehru Medical College plans a clinical trial for Chronic obstructive pulmonary disease in India (CTRI2018-07-014788)